Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study - PubMed (original) (raw)
doi: 10.2215/CJN.01381005. Epub 2006 May 17.
Zhongxin Zhang, Paulette A Lyle, Mark E Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, James P Lash, Janet B McGill, William E Mitch, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven M Snapinn, Robert Toto, Barry M Brenner; RENAAL Study Investigators
Affiliations
- PMID: 17699284
- DOI: 10.2215/CJN.01381005
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study
William F Keane et al. Clin J Am Soc Nephrol. 2006 Jul.
Abstract
Diabetic nephropathy is the most important cause of ESRD. The aim of this study was to develop a risk score from risk predictors for ESRD, with and without death, in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and to compare ability of the ESRD risk score and its components to predict ESRD. The risk score was developed from coefficients of independent risk factors from multivariate analysis of baseline variables and equals (1.96 x log [urinary albumin:creatinine ratio]) - (0.78 serum albumin [g/dl]) + (1.28 x serum creatinine [mg/dl]) - (0.11 x hemoglobin [g/dl]). It was robust with respect to severity of nephropathy, gender, race, and treatment group. The risk score for ESRD or death was comparable. The four risk predictors for progression of kidney disease were independent of therapy. For combined treatment groups, the hazard ratio between the fourth and first quartiles of the ESRD risk score was 49.0, as compared with the corresponding hazard ratios for each component: 14.7 for urinary albumin:creatinine ratio, 9.2 for serum creatinine, 5.5 for hemoglobin, and 10.2 for serum albumin. The RENAAL risk scores for ESRD with or without death emphasize the importance of identification of level of albuminuria, serum albumin, serum creatinine, and hemoglobin to predict development of ESRD in patients with type 2 diabetes and nephropathy. Although albuminuria is a strong risk factor for ESRD, the contribution of serum albumin, serum creatinine, and hemoglobin level further enhances prediction of ESRD. Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors.
Comment in
- More work to do on renin-angiotensin system blockade.
Lit YZ, Meyer TW. Lit YZ, et al. Clin J Am Soc Nephrol. 2006 Jul;1(4):611-3. doi: 10.2215/CJN.01670506. Epub 2006 Jun 21. Clin J Am Soc Nephrol. 2006. PMID: 17699265 No abstract available.
Similar articles
- Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Bakris GL, et al. Arch Intern Med. 2003 Jul 14;163(13):1555-65. doi: 10.1001/archinte.163.13.1555. Arch Intern Med. 2003. PMID: 12860578 Clinical Trial. - Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Keane WF, et al. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. doi: 10.1053/ajkd.2003.50078. Am J Kidney Dis. 2003. PMID: 12612946 Review. - Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Parving HH, et al. QJM. 2005 Feb;98(2):119-26. doi: 10.1093/qjmed/hci017. Epub 2005 Jan 17. QJM. 2005. PMID: 15655096 - Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ. Packham DK, et al. Am J Kidney Dis. 2012 Jan;59(1):75-83. doi: 10.1053/j.ajkd.2011.09.017. Epub 2011 Nov 3. Am J Kidney Dis. 2012. PMID: 22051245 - Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
Ravera M, Re M, Vettoretti S. Ravera M, et al. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S44-8. doi: 10.1681/ASN.2005121323. J Am Soc Nephrol. 2006. PMID: 16565246 Review.
Cited by
- Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review.
Walker H, Day S, Grant CH, Jones C, Ker R, Sullivan MK, Jani BD, Gallacher K, Mark PB. Walker H, et al. BMC Med. 2024 Oct 11;22(1):452. doi: 10.1186/s12916-024-03649-9. BMC Med. 2024. PMID: 39394084 Free PMC article. - Prevalence of Anemia in Type 2 Diabetic Patients and correlation with Body Mass Index and Kidney function in Palestine.
Fathi AE, Shahwan M, Hassan N, Jairoun AA, Shahwan M. Fathi AE, et al. Diabetes Metab Syndr Obes. 2024 Jun 6;17:2293-2301. doi: 10.2147/DMSO.S454916. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38859997 Free PMC article. - Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2. Cochrane Database Syst Rev. 2024. PMID: 38682786 - Prognostic Models in Nephrology: Where Do We Stand and Where Do We Go from Here? Mapping Out the Evidence in a Scoping Review.
Milders J, Ramspek CL, Janse RJ, Bos WJW, Rotmans JI, Dekker FW, van Diepen M. Milders J, et al. J Am Soc Nephrol. 2024 Mar 1;35(3):367-380. doi: 10.1681/ASN.0000000000000285. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082484 Review. - Proteinuria, measured or estimated albuminuria for risk prediction in patients with chronic kidney disease?
Kim H, Hyun YY, Joo YS, Yun HR, Kim Y, Jung JY, Jeong JC, Kim J, Park JT, Yoo TH, Kang SW, Oh KH, Han SH. Kim H, et al. Nephrol Dial Transplant. 2024 Feb 28;39(3):473-482. doi: 10.1093/ndt/gfad195. Nephrol Dial Transplant. 2024. PMID: 37723608 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical